RxDoctor Payments Data

Shannon Pitts, MD

Psychiatry · Memphis, TNNPI 1174702849

Payments from drug & device makers

$3,075in general payments, 2019–2025

Across 144 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$776
  • Johnson & Johnson$701
  • AbbVie$333
  • Lundbeck LLC$213
  • Teva Pharmaceuticals USA, Inc.$210
  • Neurocrine Biosciences, Inc.$149
  • plus $692 from 13 others

What the payments were for

  • Food & beverage$3,075100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,075 in reported general payments places this provider in the 80th percentile of 503 psychiatry providers in Tennessee.

See all psychiatry providers in Tennessee

Medicare billing

Part B allowed, 2024
$29,180
Medicare patients
64
Services billed
258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$141,190
Invega SustennaPaliperidone Palmitate16$44,443
Desvenlafaxine Succinate ErDesvenlafaxine Succinate19$1,008
Trazodone Hcl52$890
Buspirone Hcl65$616
Olanzapine49$613
Duloxetine Hcl42$564
Aripiprazole30$454
Quetiapine Fumarate33$410
Oxcarbazepine16$392
Venlafaxine Hcl ErVenlafaxine Hcl23$383
Mirtazapine28$322
Sertraline Hcl46$266
Fluoxetine Hcl32$264
Bupropion XlBupropion Hcl15$228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$149$141,19017 claims
Johnson & JohnsonInvega Sustenna$701$44,44316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 503 psychiatry providers in Tennessee.

Other psychiatry in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →